期刊文献+

布地奈德混悬液和异丙托溴铵溶液雾化吸入治疗慢性阻塞性肺疾病急性加重期临床观察 被引量:6

Clinical observation on the effect of combination of budesonide and compomld ipratropium bromide aerosol used in treatment of patients with acute exacerbation of chronic obstructive pulmonary disease
下载PDF
导出
摘要 目的:观察布地奈德联合复方异丙托溴铵雾化吸入对慢性阻塞性肺疾病急性加重期(AECOPD)的临床疗效。方法:对70例AECOPD住院患者随机分为观察组和对照组各35例,观察组在常规治疗的基础上给予布地奈德和复方异丙托溴铵雾化吸入治疗,对照组在常规治疗基础上给予复方异丙托溴铵雾化吸入治疗,分析两组的临床疗效。结果:两组治疗前后呼吸困难评分、肺功能和血气分析等比较,差异有统计学意义(P<0.05)。结论:治疗后两组间各对应指标,差异有统计学意义(P<0.05)。结论:布地奈德联合复方异丙托溴铵雾化吸入对AECOPD能迅速缓解症状,畅通气道,改善肺功能,疗效优于单一用药,是治疗AECOPD的有效选择。 Objective To study the effect of budesonide combined with compomld ipratropium bromide aerosol in treatment of patients with acute exacerbation of chronic obstructive pulmonary disease.Method Seventy patients with AECOPD were randomly divided into observation group(35 cases) and control group(35 cases).Patients in observation group were treated with conventional therapy of budesonide and compomld ipratropium bromide aerosol besides routine therapeutic regimen and patients in control group were treated with compomld ipratropium bromide aerosol.The clinical efficacy was compared and analyzed between patients of these two groups.Results The differences in dyspnea scores,lung function and blood gas analysis were compared before and after the treatment,and their difference had statistically significant(P0.05).The difference in corresponding indicators between these two groups had statistically significant(P0.05).Conclusion Budesonide and compomld ipratropium bromide aerosol can rapidly relieve symptoms of AECOPD,smooth airway and improve lung function,it is more effective than the application of single drug,and it is an effective choice for treatment of patients with AECOPD.
作者 史鹏 安东善
机构地区 吉林省人民医院
出处 《吉林医学》 CAS 2012年第31期6740-6741,共2页 Jilin Medical Journal
关键词 慢性阻塞性肺疾病急性加重期 雾化吸入 布地奈德 复方异丙托溴铵 AECOPD Inhalation Budesonide Compomld ipratropium bromide aerosol
  • 相关文献

参考文献3

二级参考文献32

  • 1慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8233
  • 2Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med, 2007,176:753-760.
  • 3Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med, 2007,176:532-555.
  • 4Akkoca Yildiz O, Onen ZP, Demir G, et al. Is there any difference between effects of ipratropium bromide and formoterol on exercise capacity in moderate COPD patients? Tuberk Toraks, 2006, 54 : 105-113.
  • 5Hanania NA, Donohue JF. Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. Proc Am Thorac Soc, 2007, 4: 526-534.
  • 6In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day muhicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest, 1994,105 : 1411-1419.
  • 7Routine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study Group. Chest, 1997,112:1514-1521.
  • 8Campbell S. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. Arch Intern Med, 1999, 159:156-160.
  • 9Wesseling G, Mostert R, Wouters EF. A comparison of effects of anticholinergic and beta 2-agonist and combination therapy on respiratory impedance in COPD. Chest, 1992,101:166-173.
  • 10Snow V, Lascher S, Mottur-Pilson C, et al. The evidence base for management of acute exacerbations of COPD: clinical practice guideline, part 1. Chest, 2001,119:1185-1190.

共引文献162

同被引文献74

二级引证文献101

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部